Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04918615
Other study ID # D-IC-040
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 28, 2021
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source Shanghai MicroPort Medical (Group) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Microport sirolimus drug coated balloon catheter for the treatment of coronary bifurcation lesions.


Description:

PROMISE-BIF is a prospective, multicenter, randomized controlled, non-inferior clinical trial, which would enroll about 234 participants. All participants will undergo PCI with sirolimus drug coated balloon catheter or paclitaxel drug coated balloon catheter and be followed-up to 24 months. The Target Lesion defined as the true bifurcation, include the main branch and side branch lesion. The bifurcation lesions were classified by Medina (1.1.1, 1.0.1, and 0.1.1). The image data will be analyzed and evaluated independently by a third-party imaging laboratory.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 236
Est. completion date December 31, 2024
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Male or non-pregnant female ages 18-80 years old - Participants with myocardial ischemia, stable or unstable angina pectoris, old myocardial infarction, or Stabled myocardial infarction (occurred more than 7 days before enrollment, including non-ST elevation and ST elevation myocardial infarction) - Participants are are eligible to undergo any type of coronary revascularization surgery, such as balloon angioplasty, stenting, and coronary artery bypass grafting (CABG); - Participants Can understand the trial's purpose, voluntarily participate and acknowledge all the risks and benefits, providing written informed consent and are willing to accept invasive radiographic during the follow-up period. - Angiography confirmed as De novo bifurcation lesion, the stenosis rate of side branch (diameter) =70% - Suitable for PCI and the side branch lesions is not expected to stent implantation, and no DCB treatment for the main branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches - Up to 2 vessels that need to be treated, total intended treat lesions' amount will not exceed 3 - At most one primary bifurcation lesion that needs treatment (including Medina classification 1.1.1, 1.0.1, 0.1.1), ostium stenosis degree (diameter) =70% (visual); - Patients are suitable for PCI and side branch is not expected to implant a stent, the main branch will not apply drug coated balloon; the main branch will implant a stent, usually the main branch and side branch will have Kissing Balloon Inflation - The side branch is pre-dilated successfully, no C or upper grade dissection, no tear or other complications occurred, residual stenosis =50%, TIMI3 - The reference diameter of the target lesion side branch is 2.0~4.0 mm, the length of the lesion in side branch is =38 mm, and the length of the lesion in main branch is =70 mm Exclusion Criteria: - Any AMI occurred within 1 week before operation - Unstable arrhythmias, such as high-risk ventricular premature beats, ventricular tachycardia - severe heart failure (above NYHA IV) or Left ventricular ejection fraction (LVEF) <30% (ultrasound or left ventricular angiography) - Renal function insufficiency: Serum creatinine >177µmol/L; Or undergoing hemodialysis; - definite hemorrhagic tendency, antiplatelet and anticoagulant therapy contraindication and unable to anticoagulant therapy; - PCI planned within 1 year - Have a history of peptic ulcer or gastrointestinal hemorrhage in the past 6 months; Have a history of cerebrovascular accidents (stroke) such as cerebral hemorrhage, cerebral infarction in the past 6 months; - allergic to contrast agent, paclitaxel, and rapamycin and its derivatives - Has been diagnosed as advanced cancer and other serious diseases, lifespan are expected less than 12 months or hard to complete the 12-month follow up; - Patients who are considered to have poor compliance and cannot complete the trial in accordance with requirements; Or other reasons that considered by the investigator, it be unsuitable to enroll the participant; - Be participating in any other clinical trials, or have participated in clinical trials of other drugs or medical devices before being selected but have not reached the timeline of the primary endpoint; - Female who are pregnant or breastfeeding (women who may become pregnant must undergo a pregnancy test within 7 days before the baseline surgery);Or have fertility plan/can not have adequate contraception during the study period - Three vessel disease and all the vessels need revasculization - Left main and its bifurcation lesions; - thrombus in the bifurcation lesion, or tortuose lesion that the balloon catheter will not pass through; - Side branch lesion segment of target lesion is a total occlusion lesion - side branch is severely calcified, and cannot be pre-dilated or dilated while do kissing balloon inflation; - Target lesion (including main branch and branch) is in-stent re-stenosis - Dissection above grade C or residual stenosis >50% after pre-dilation of the target lesion branch vessel disease or double kissing balloon dilation; - Two or more non-target lesions that need to be treated, the non-target lesion cannot be processed before the target lesion or the treatment fails;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PCI
Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.

Locations

Country Name City State
China General Hospital of the PLA Northern Theater Command Shengyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Shanghai MicroPort Medical (Group) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Immediate Success Endpoint Immediate Success Endpoint including Technical success, Lesion success and Procedural success.
Technical success defined as the success of the study device in reaching the target lesion branch vascular lesions, dilatating and retracting successfully with residual stenosis of the branch vessel lesion =30%(visual inspection); Lesion success defined as the main and branch vessels of the target lesion residual stenosis Residual stenosis = =30%, furthermore blood flow is TIMI 3 (visual inspection) after treatment with any interventional method Procedural success defined as the absence of device-related composite end point events during the hospitalization period (up to 7 days after surgery) on the basis of Lesion success.
7 days
Other DoCE Defined as a composite of cardiac death, target vessel-related MI, or ischemia-driven side branch lesion revascularization events at 30 days, 6 months, 9 months and 12 months 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other PoCE Defined as a composite rate of all cause death, all MI or any revasculariztion at 30 days, 6 months, 9 months, and 12 months 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Death Cardiac, Vascular, Non-cardiovascular related 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Myocardial infarction Target vessel related, Non-target vessel related 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Target lesion Revascularization Lesion revascularization in main branch, side branch or both, ischemic driven or non-ischemic driven 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Target vessel Revascularization Ischemia-driven , Not ischemia-driven 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Any coronary revascularization Ischemia-driven , Not ischemia-driven 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other Thrombotic events ARC defined: acute, subacute, late 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other AE & SAEs rate 30 days, 6 months, 9 months, 12 months, 24 months post-procedure
Other side branch re-stenosis rate the proportion of patients with re-stenosis in the side branch, stenosis degree >50% 9 months
Other main branch re-stenosis rate the proportion of patients with re-stenosis in the main branch, stenosis degree >50% 9 months
Other In-segment late loss of the main branch (mm) The minimum lumen diameter (MLD) immediately after stent implantation was subtracted from the MLD at follow-up 9 months
Other In-segment Stenosis degree of the main branch (%) 9 months
Primary Percent Diameter Stenosis (DS) of side branch Stenosis of lumen diameter of lesion segment of the side branch 9 months
Secondary Late lumen loss (LLL) of side branch late lumen loss of lesion segment of the side branch 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A